Today, the Commission, through its Health Emergency Preparedness and Response Authority (HERA) and the European Investment Bank, have signed an agreement worth €20 million with the French biopharmaceutical company Fabentech. This will support the company's development and deployment of its broad-spectrum therapeutics to combat biological threats to public health.

HERA's threat analysis has demonstrated the importance of developing Fabentech's technology platform, which relies on the production of broad-spectrum polyclonal antibody fragments, which recognise and neutralise pathogens and toxins in the human body. Thanks to its integrated research and development (R&D) and bioproduction capabilities, Fabentech aims to rapidly develop and produce new immunotherapies, contributing to a more effective response in public health emergencies.

Today's agreement is the first in its kind under HERA Invest. More investments are in the pipeline with other European companies. They will stimulate innovation to respond to priority health threats, such as pathogens with high pandemic potential, chemical, biological, radiological and nuclear (CBRN) threats, and resistance to antibiotics.